CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Introduction of immuno-chemotherapy in the treatment options of CLL and SLL changed the treatment paradigm of these diseases. Presently, first-line therapies for CLL/SLL include targeted therapies (e.g. ibrutinib, acalabrutinib) or combined immuno-chemotherapy regimens (e.g., fludarabine, cyclophosphamide, and rituximab for patients aged \<65 years without del17p/TP53 mutations or bendamustine and rituximab for patients ≥65 years who have additional comorbidities). Despite the gradual introduction of targeted therapies, new treatment strategies efficacious for patients ineligible for/unrespon

Trial Details

NCT ID
NCT04704323
Phase
PHASE1
Sponsor
Catapult Therapeutics
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • CAP-100
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Madrid, Spain|40.4165,-3.70256
  • Santander, Spain|43.46589,-3.80493

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Able to understand and sign a written informed consent document.
  • Eastern Cooperative Oncology Group (ECOG) performance status 0, 1 or 2.
  • Relapsed or refractory to at least two (2) prior standard systemic treatment regimen for CLL or SLL (USA).

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →